Perspective Therapeutics, Inc. (CATX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Grant revenue | 290 | 342 | 369 | |
| Research and development | 16,620 | 14,332 | 12,028 | |
| General and administrative | 7,709 | 7,842 | 6,975 | |
| Total operating expenses | 24,329 | 22,174 | 19,003 | |
| Operating loss | -24,039 | -21,832 | -18,634 | |
| Other income from a related party (note 3) | - | 1,400 | - | |
| Interest income | 2,159 | 2,384 | 3,581 | |
| Equity in loss of affiliate | - | -1 | - | |
| Interest and other expense | 119 | 128 | 69 | |
| Total non-operating income, net | 2,040 | 3,655 | 3,512 | |
| Net loss from continuing operations | -21,999 | -18,177 | -15,122 | |
| Net gain (loss) from discontinued operations | 514 | - | - | |
| Net loss before deferred income tax benefit | - | - | -15,122 | |
| Net loss | -21,485 | -18,177 | -15,122 | |
| Basic and diluted (in shares) | 74,235,000 | 72,357,000 | 70,629,000 | |
| Basic loss per share | -0.29 | -0.25 | -0.21 | |
| Diluted loss per share | -0.29 | -0.25 | -0.21 | |
| Weighted average number of shares outstanding, diluted, total | 74,235,000 | 72,357,000 | 70,629,000 | |